1[1]Pegram M,Hsu S,Lewis G,et al.Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers[J].Oncogene,1999,18:2241-2251.
2[2]Baselga J,Norton L,Albanell J,et al.Recombinant humanized antiHER2 antibody(Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts[J].Cancer Res,1998,58:2825-2831.
3[3]Leyland-Jones B,Hemmings F,Amold A,et al.Ayoub JP.Pharmacokinetics of Herceptin Administered with Paclitaxel every three weeks[J].Breast Cancer Res and Treat,2000,64:124.
4[4]Vogel C,Cobleigh M,Tripathy D,et al.First-line single-agent Herceptin (H) therapy for women with HER2-overexpressing metastatic breast cancer (MBC)[J].Eur J Cancer,2000.36(Suppl5):2000,S53.
5Ewer M,Benjamin RS.Cardiotoxicity of chemotherapeutic drugs[A].Perry MC The chemotherapy sourcebook[M].Philadelphia:Lippincott,Williams & Wilkins,2001,458～468.
6Theodoulou M,Seidman AD.Cardiac effects of adjuvant therapy for early breast cancer[J].Semin Onco1,2003,30 (6):730～739.
7Cardinale D,Sandri M,Martinoni A,et al.Myocardial injury revealed by plasma troponin Ⅰ breast cancer treated with high-dose chemotherapy[J].Ann Oncol,2002,13 (5):710～715.
8Hequet O,Le QH,Moullet I,et al.Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults[J].J Clin Oncol,2004,22(10):1864～1871.
9Harris L,Batist G,Belt R,et al.Liposomeencapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma[J].Cancer,2002,94 (1):25～36.
10Lipshultz SE,Rifai N,Dalton VM,et al.The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastie leukemia[J].N Engl J Med,2004,351 (2):145 ～153.
5Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER- 2positive breast cancer[J]. New Engl Med,2005,353 (16) :673 - 684.
